ArielaNoyMD

Lymphoma Service, Division of Hematology, Memorial Sloan-Kettering Center, NY, NY

Overview of Dr. Noy

I am a board-certified hematologist and medical oncologist with a major focus on treating cancers of the lymphoid immune system, in particular lymphomas and certain forms of leukemia. HIV-related lymphomas are one my main areas of interest. To provide the best treatment to each patient with these diseases, I work very closely with a team of expert specialists.

My research interests include HIV-related cancers, especially lymphoma; molecular detection of minimal disease in patients on lymphoma trials; and a variety of other lymphoma-related projects, including new treatments, imaging, and quality of life.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(714) 706-3837

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1993 - 1997
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1990 - 1993
Perelman School of Medicine at the University of PennsylvaniaClass of 1990

Certifications & Licensure

FL State Medical License 2022 - Present
CT State Medical License 2024 - 2025
NJ State Medical License 2022 - 2025
NY State Medical License 1991 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients
Completed
Phase 3
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma Start of enrollment: 2005 Jun 01
Completed
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma Start of enrollment: 2006 Sep 01
Completed
Phase 2
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
Completed
Phase 1
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
Autologous Transplant in HIV Patients (BMT CTN 0803) Start of enrollment: 2010 Apr 01
Completed
Phase 2
Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Start of enrollment: 2010 Oct 06
Completed
Phase 1, Phase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma Start of enrollment: 2013 Mar 07
Active, not recruiting
Phase 1, Phase 2
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Start of enrollment: 2013 Dec 01
Completed
Phase 2
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Start of enrollment: 2014 Sep 01
Terminated
Phase 1
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Start of enrollment: 2016 Jun 23
Active, not recruiting
Phase 1, Phase 2
Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy Start of enrollment: 2016 Nov 01
Terminated
Early Phase 1
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations Start of enrollment: 2018 Dec 31
Active, not recruiting
Phase 2
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma Start of enrollment: 2019 Dec 23
Active, not recruiting
Phase 3
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma Start of enrollment: 2021 May 24
Recruiting
Early Phase 1
Roles: Principal Investigator, Contact
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers Start of enrollment: 2023 May 10
Recruiting
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

67 citations
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.
David Sermer, Connie L Batlevi, M. Lia Palomba, Gunjan L. Shah, Richard J. Lin
Blood Advances. 2020-10-13
454 citations
Developing a Cancer-Specific Geriatric Assessment: A Feasibility Study
Arti Hurria, Supriya Gupta, Marjorie G. Zauderer, Enid L. Zuckerman, Harvey J. Cohen
Cancer. 2005-11-01
299 citations
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
Tarun Kewalramani, Andrew D. Zelenetz, Stephen D. Nimer, Carol S. Portlock, David J. Straus
Blood. 2004-05-15

Abstracts/Posters

MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803...
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatm...
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 107
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
Ariela Noy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Press Mentions

You Make the Call: Is Hypogammaglobulinemia Alone an Indication for Treatment for CLL?November 1st, 2020
Expert Q&A: Understanding the Oncogenic Role of HIV in Burkitt LymphomaAugust 27th, 2020
Data on Rafael Pharmaceuticals’ CPI-613® (Devimistat) in Patients with Relapsed Burkitt Lymphoma to Be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & ExpositionDecember 3rd, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Other Languages

Spanish, Hebrew

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment